Denali Therapeutics Inc. [NASDAQ: DNLI] closed the trading session at $64.64 on 05/25/21. The day’s price range saw the stock hit a low of $60.50, while the highest price level was $64.95. The company report on May 25, 2021 that Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture.
Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet’s interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges, announced the closing of a Series C financing round totaling $88.9 million. Joining founder and principal backer Flagship Pioneering is Stage 1 Ventures, Bluwave Capital, Alexandria Venture Investments, and others. With this financing, Invaio has raised more than $142 million since its founding in 2018.
“Our ambition is to build the most impactful and valuable crop health company on the planet,” said Ignacio Martinez, Co-Founder and CEO of Invaio. “The world is changing quickly, and food production practices must adapt to keep pace with evolving consumer demands, changing environmental conditions and increased stress on ecological resources.”.
The stocks have a year to date performance of -22.83 percent and weekly performance of 16.45 percent. The stock has been moved at 3.67 percent over the last six months. The stock has performed 7.39 percent around the most recent 30 days and changed -3.18 percent over the most recent 3-months.
If compared to the average trading volume of 490.17K shares, DNLI reached to a volume of 2615046 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Denali Therapeutics Inc. [DNLI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DNLI shares is $78.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DNLI stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Denali Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 18, 2021. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $80 to $95. The new note on the price target was released on February 26, 2021, representing the official price target for Denali Therapeutics Inc. stock. Previously, the target price had yet another raise to $105, while Cantor Fitzgerald analysts kept a Overweight rating on DNLI stock. On November 11, 2020, analysts increased their price target for DNLI shares from 65 to 80.
The Average True Range (ATR) for Denali Therapeutics Inc. is set at 3.31, with the Price to Sales ratio for DNLI stock in the period of the last 12 months amounting to 23.08. The Price to Book ratio for the last quarter was 7.07, with the Price to Cash per share for the same quarter was set at 11.64. Price to Free Cash Flow for DNLI in the course of the last twelve months was 18.89 with Quick ratio for the last quarter at 26.20.
DNLI stock trade performance evaluation
Denali Therapeutics Inc. [DNLI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 16.45. With this latest performance, DNLI shares gained by 7.39% in over the last four-week period, additionally plugging by 3.67% over the last 6 months – not to mention a rise of 149.48% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DNLI stock in for the last two-week period is set at 66.37, with the RSI for the last a single of trading hit 75.05, and the three-weeks RSI is set at 60.54 for Denali Therapeutics Inc. [DNLI]. The present Moving Average for the last 50 days of trading for this stock 56.37, while it was recorded at 59.91 for the last single week of trading, and 56.55 for the last 200 days.
Denali Therapeutics Inc. [DNLI]: An insightful look at the core fundamentals
Denali Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 26.20 and a Current Ratio set at 26.20.
Earnings per share (EPS) analysis for Denali Therapeutics Inc. [DNLI] stock
With the latest financial reports released by the company, Denali Therapeutics Inc. posted -0.56/share EPS, while the average EPS was predicted by analysts to be reported at -0.6/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 6.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DNLI.
Denali Therapeutics Inc. [DNLI]: Insider Ownership positions
There are presently around $5,239 million, or 76.80% of DNLI stock, in the hands of institutional investors. The top three institutional holders of DNLI stocks are: BAILLIE GIFFORD & CO with ownership of 12,995,197, which is approximately 6.603% of the company’s market cap and around 2.60% of the total institutional ownership; CRESTLINE MANAGEMENT, LP, holding 9,984,836 shares of the stock with an approximate value of $645.42 million in DNLI stocks shares; and VANGUARD GROUP INC, currently with $527.88 million in DNLI stock with ownership of nearly 3.046% of the company’s market capitalization.
124 institutional holders increased their position in Denali Therapeutics Inc. [NASDAQ:DNLI] by around 6,081,218 shares. Additionally, 96 investors decreased positions by around 13,484,103 shares, while 25 investors held positions by with 61,484,380 shares. The mentioned changes placed institutional holdings at 81,049,701 shares, according to the latest SEC report filing. DNLI stock had 44 new institutional investments in for a total of 1,129,300 shares, while 27 institutional investors sold positions of 561,633 shares during the same period.